CN104379758A - 用于肾损伤和肾衰竭的诊断及预后的方法和组合物 - Google Patents

用于肾损伤和肾衰竭的诊断及预后的方法和组合物 Download PDF

Info

Publication number
CN104379758A
CN104379758A CN201380020012.4A CN201380020012A CN104379758A CN 104379758 A CN104379758 A CN 104379758A CN 201380020012 A CN201380020012 A CN 201380020012A CN 104379758 A CN104379758 A CN 104379758A
Authority
CN
China
Prior art keywords
hours
subject
renal
likelihood
comprises determining
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380020012.4A
Other languages
English (en)
Chinese (zh)
Inventor
J·安德伯格
J·格雷
P·麦克弗森
K·中村
J·P·坎普夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astute Medical Inc
Original Assignee
Astute Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astute Medical Inc filed Critical Astute Medical Inc
Publication of CN104379758A publication Critical patent/CN104379758A/zh
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
    • A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
    • A61M1/1601—Control or regulation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/04—Liquids
    • A61M2202/0413—Blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/75—General characteristics of the apparatus with filters
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
CN201380020012.4A 2012-02-27 2013-02-27 用于肾损伤和肾衰竭的诊断及预后的方法和组合物 Pending CN104379758A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261603912P 2012-02-27 2012-02-27
US201261603906P 2012-02-27 2012-02-27
US61/603,906 2012-02-27
US61/603,912 2012-02-27
PCT/US2013/028000 WO2013130591A1 (en) 2012-02-27 2013-02-27 Methods and compositions for diagnosis and prognosis of renal injury and renal failure

Publications (1)

Publication Number Publication Date
CN104379758A true CN104379758A (zh) 2015-02-25

Family

ID=49083233

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380020012.4A Pending CN104379758A (zh) 2012-02-27 2013-02-27 用于肾损伤和肾衰竭的诊断及预后的方法和组合物

Country Status (9)

Country Link
US (1) US20150010929A1 (enExample)
EP (1) EP2820146A4 (enExample)
JP (1) JP2015508181A (enExample)
CN (1) CN104379758A (enExample)
AU (1) AU2013226181A1 (enExample)
CA (1) CA2865559A1 (enExample)
HK (1) HK1204339A1 (enExample)
IN (1) IN2014MN01759A (enExample)
WO (1) WO2013130591A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107709993A (zh) * 2015-06-11 2018-02-16 阿斯图特医药公司 用于肾损伤和肾衰竭的诊断和预后的方法和组合物

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013113018A1 (en) * 2012-01-28 2013-08-01 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CA3012985A1 (en) 2015-01-27 2016-08-04 Kardiatonos, Inc. Biomarkers of vascular disease

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102246035A (zh) * 2008-10-21 2011-11-16 阿斯图特医药公司 用于诊断和预后肾损伤和肾衰竭的方法和组合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070233391A1 (en) * 2002-03-07 2007-10-04 Cambridge University Technical Service Limited (CUTS) Scd fingerprints
WO2005024603A2 (en) * 2003-09-10 2005-03-17 The Board Of Regents Of The University Of Texas System Methods for detecting, diagnosing and treating human renal cell carcinoma
FR2872579B1 (fr) * 2004-06-30 2006-11-24 Pasteur Institut Detection de la tuberculose et de l'infection par mycobacterium tuberculosis a l'aide de hbha
US20090178145A1 (en) * 2005-05-11 2009-07-09 The Procter & Gamble Company Methods and targets for identifying compounds for regulating angiogenesis
US7623910B2 (en) * 2006-03-10 2009-11-24 University Of Rochester ECG-based differentiation of LQT1 and LQT2 mutation
CA2751435A1 (en) * 2009-02-06 2010-08-12 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and failure
EP2427494B1 (en) * 2009-05-08 2017-10-18 Novartis AG Methods of modulating fibrosis using bone morphogenetic protein-9 (bmp-9) modulators
WO2013096740A1 (en) * 2011-12-21 2013-06-27 Alere San Diego Inc. Methods and compositions for assigning likelihood of chronic kidney disease progression

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102246035A (zh) * 2008-10-21 2011-11-16 阿斯图特医药公司 用于诊断和预后肾损伤和肾衰竭的方法和组合物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
EREK C. ADAMS等: "Follistatin-like 1 regulates renal IL-1β expression in cisplatin nephrotoxicity", 《AM J PHYSIOL RENAL PHYSIOL》 *
SVENNEUIG K ET AL: "Increased syndecan-1 in serum is related to early nephropathy in type 1 diabetes mellitus patients", 《DIABETOLOGIA》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107709993A (zh) * 2015-06-11 2018-02-16 阿斯图特医药公司 用于肾损伤和肾衰竭的诊断和预后的方法和组合物

Also Published As

Publication number Publication date
EP2820146A1 (en) 2015-01-07
EP2820146A4 (en) 2015-12-16
AU2013226181A1 (en) 2014-09-18
JP2015508181A (ja) 2015-03-16
WO2013130591A1 (en) 2013-09-06
US20150010929A1 (en) 2015-01-08
IN2014MN01759A (enExample) 2015-07-03
HK1204339A1 (en) 2015-11-13
CA2865559A1 (en) 2013-09-06

Similar Documents

Publication Publication Date Title
CN105074466B (zh) 用于肾损伤和肾衰竭的诊断及预后的方法和组合物
CN102791885B (zh) 用于肾损伤和肾衰竭的诊断及预后的方法和组合物
CN103874923B (zh) 用于肾损伤和肾衰竭的诊断及预后的方法和组合物
CN102439441B (zh) 用于肾损伤和肾衰竭的诊断及预后方法和组合物
CN102725636B (zh) 用于肾损伤和肾衰竭的诊断及预后的方法和组合物
JP7217796B2 (ja) 腎障害および腎不全の診断および予後のための方法および組成物
CN102711827B (zh) 用于肾损伤和肾衰竭的诊断及预后的方法和组合物
CN103080743B (zh) 用于肾损伤和肾衰竭的诊断及预后的方法和组合物
CN102576011B (zh) 用于肾损伤和肾衰竭的诊断及预后的组合物和方法
CN102597258B (zh) 肾损伤和肾衰竭的诊断及预后
CN103238068B (zh) 用于肾损伤和肾衰竭的诊断及预后的方法和组合物
CN102792161A (zh) 肾损伤和肾衰竭的诊断及预后的方法及组合物
CN102725635B (zh) 用于肾损伤和肾衰竭的诊断及预后的方法和组合物
HK1200218A1 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN103858008B (zh) 用于肾损伤和肾衰竭的诊断及预后的方法和组合物
CN102576012B (zh) 用于肾损伤和肾衰竭的诊断及预后方法和组合物
CN102884205B (zh) 用于肾损伤和肾衰竭的诊断及预后的方法和组合物
CN107003325A (zh) 用于诊断和预后肾损伤和肾衰竭的方法和组合物
CN104379758A (zh) 用于肾损伤和肾衰竭的诊断及预后的方法和组合物
CN104335045B (zh) 用于肾损伤和肾衰竭的诊断及预后的方法和组合物
CN104583774A (zh) 用于肾损伤和肾衰竭的诊断及预后的方法和组合物
CN105209914B (zh) 用于肾损伤和肾衰竭的诊断及预后的方法和组合物
CN107709993A (zh) 用于肾损伤和肾衰竭的诊断和预后的方法和组合物
HK1162617B (zh) 腎損傷和腎衰竭的診斷和預後
HK1203620B (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1204339

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20150225

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1204339

Country of ref document: HK